Human Leukocyte Antigen G Polymorphism and Expression Are Associated with an Increased Risk of Non-Small-Cell Lung Cancer and Advanced Disease Stage

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Aug 13

PMID 27517300

Citations 10

Authors

Amira Ben Amor

Karine Beauchemin

Marie-Claude Faucher

Agnes Hamzaoui

Kamel Hamzaoui

Michel Roger

Affiliations

Soon will be listed here.

Abstract

Human leukocyte antigen (HLA)-G acts as negative regulator of the immune responses and its expression may enable tumor cells to escape immunosurveillance. The purpose of this study was to investigate the influence of HLA-G allelic variants and serum soluble HLA-G (sHLA-G) levels on risk of non-small-cell lung cancer (NSCLC). We analyzed 191 Caucasian adults with NSCLC and 191 healthy subjects recruited between January 2009 and March 2014 in Ariana (Tunisia). Serum sHLA-G levels were measured by immunoassay and HLA-G alleles were determined using a direct DNA sequencing procedures. The heterozygous genotypes of HLA-G 010101 and -G 010401 were associated with increased risks of both NSCLC and advanced disease stages. In contrast, the heterozygous genotypes of HLA-G 0105N and -G 0106 were associated with decreased risks of NSCC and clinical disease stage IV, respectively. Serum sHLA-G levels were significantly higher in patients with NSCLC and particularly in those with advanced disease stages compared to healthy subjects. The area under the receiver-operating characteristic (ROC) curves was 0.82 for controls vs patients. Given 100% specificity, the highest sensitivity achieved to detect NSCLC was 52.8% at a cutoff value of 24.9 U/ml. Patients with the sHLA-G above median level (≥ 50 U/ml) had a significantly shorter survival time. This study demonstrates that HLA-G allelic variants are independent risk factors for NSCLC. Serum sHLA-G levels in NSCLC patients could be useful biomarkers for the diagnostic and prognosis of NSCLC.

Citing Articles

Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.

Taylor M, Naing A, Powderly J, Woodard P, Chung L, Lin W J Immunother Cancer. 2024; 12(11).

PMID: 39567210 PMC: 11580248. DOI: 10.1136/jitc-2024-010006.

Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.

Wang S, Wang J, Xia Y, Zhang L, Jiang Y, Liu M J Transl Med. 2024; 22(1):130.

PMID: 38310272 PMC: 10838004. DOI: 10.1186/s12967-024-04938-w.

HLA-G and single nucleotide polymorphism (SNP) associations with cancer in African populations: Implications in personal medicine.

Adolf I, Almars A, Dharsee N, Mselle T, Akan G, Nguma I Genes Dis. 2022; 9(5):1220-1233.

PMID: 35873024 PMC: 9293715. DOI: 10.1016/j.gendis.2021.06.004.

HLA-G 14bp Ins/Del Polymorphism, Plasma Level of Soluble HLA-G, and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients.

Bucova M, Kluckova K, Kozak J, Rychly B, Suchankova M, Svajdler M Diagnostics (Basel). 2022; 12(5).

PMID: 35626255 PMC: 9139224. DOI: 10.3390/diagnostics12051099.

HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers.

Li P, Wang N, Zhang Y, Wang C, Du L Front Immunol. 2021; 12:791535.

PMID: 34868081 PMC: 8636042. DOI: 10.3389/fimmu.2021.791535.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Kowal A, Wisniewski A, Kusnierczyk P, Jankowska R . Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer. Thorac Cancer. 2015; 6(5):613-9. PMC: 4567007. DOI: 10.1111/1759-7714.12232. View

Cao M, Yie S, Liu J, Ye S, Xia D, Gao E . Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011; 78(2):120-8. DOI: 10.1111/j.1399-0039.2011.01716.x. View

Yan W, Liu D, Lu H, Li Y, Zhang X, Lin A . Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients. J Cell Mol Med. 2015; 19(4):778-85. PMC: 4395192. DOI: 10.1111/jcmm.12400. View

Wisniewski A, Kowal A, Wyrodek E, Nowak I, Majorczyk E, Wagner M . Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer. Tissue Antigens. 2015; 85(6):466-75. DOI: 10.1111/tan.12561. View

Ferguson R, Ramanakumar A, Koushik A, Coutlee F, Franco E, Roger M . Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix. Int J Cancer. 2011; 131(3):E312-9. DOI: 10.1002/ijc.27356. View

Sheu J, Shih I . HLA-G and immune evasion in cancer cells. J Formos Med Assoc. 2010; 109(4):248-57. DOI: 10.1016/S0929-6646(10)60050-2. View

Dunn G, Old L, Schreiber R . The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2):137-48. DOI: 10.1016/j.immuni.2004.07.017. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Chen Y, Gao X, Deng Y, Zhang H . Relationship between HLA-G gene polymorphism and the susceptibility of esophageal cancer in Kazakh and Han nationality in Xinjiang. Biomarkers. 2011; 17(1):9-15. DOI: 10.3109/1354750X.2011.633242. View

11.

Schutt P, Schutt B, Switala M, Bauer S, Stamatis G, Opalka B . Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol. 2010; 71(5):489-95. DOI: 10.1016/j.humimm.2010.02.015. View

12.

Ferguson R, Ramanakumar A, Richardson H, Tellier P, Coutlee F, Franco E . Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. Hum Immunol. 2011; 72(4):337-41. DOI: 10.1016/j.humimm.2011.01.010. View

13.

Ghandri N, Gabbouj S, Farhat K, Bouaouina N, Abdelaziz H, Nouri A . Association of HLA-G polymorphisms with nasopharyngeal carcinoma risk and clinical outcome. Hum Immunol. 2010; 72(2):150-8. DOI: 10.1016/j.humimm.2010.10.006. View

14.

Jeong S, Park S, Park B, Park Y, Kwon O, Kim H . Human leukocyte antigen-G (HLA-G) polymorphism and expression in breast cancer patients. PLoS One. 2014; 9(5):e98284. PMC: 4037222. DOI: 10.1371/journal.pone.0098284. View

15.

Lin A, Zhu C, Chen H, Chen B, Zhang X, Zhang J . Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer. J Cell Mol Med. 2009; 14(9):2318-29. PMC: 3822572. DOI: 10.1111/j.1582-4934.2009.00858.x. View

16.

Fainardi E, Castellazzi M, Stignani M, Morandi F, Sana G, Gonzalez R . Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci. 2010; 68(3):433-51. PMC: 11114687. DOI: 10.1007/s00018-010-0584-3. View

17.

Urosevic M, Kurrer M, Kamarashev J, Mueller B, Weder W, Burg G . Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001; 159(3):817-24. PMC: 1850480. DOI: 10.1016/S0002-9440(10)61756-7. View

18.

Rebmann V, van der Ven K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H . Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens. 2001; 57(1):15-21. DOI: 10.1034/j.1399-0039.2001.057001015.x. View

19.

Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F . The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother. 2004; 53(10):904-10. PMC: 11032983. DOI: 10.1007/s00262-004-0517-9. View

20.

Ferrone S, Marincola F . Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995; 16(10):487-94. DOI: 10.1016/0167-5699(95)80033-6. View